457669AA7
Insmed Incorporated
Could not find a ticker for this position, may be a filing error
A maker of inhaled medicines for rare lung diseases, Insmed sells ARIKAYCE for a stubborn bacterial lung infection and BRINSUPRI for bronchiectasis, with gene therapies for muscular dystrophy and ALS in the works. Founded in 1988 in Richmond, Virginia, it began by developing insulin-like growth factor proteins before turning to respiratory care. Its ARIKAYCE was the first drug approved under the FDA's Limited Population Pathway, designed for serious infections in small patient groups.
CONVERTIBLEUnderlying: INSMCUSIP: 457669AA7HealthcareUS1 derivative reporter
1.75% Convertible Senior Notes due 2025, redeemed August 9, 2024
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
